Final Analysis of Lenvatinib + Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma With or Without Bone Metastases in CLEAR

Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.

Related Content:

Rapid Readouts
MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer
Darovasertib Plus Crizotinib in First-Line Metastatic Uveal Melanoma: Phase 1/2 OptimUM-01 Results
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial